181630-15-9

Basic information

• Product Name: Picoplatin
• Synonyms: ZD0473;Amminedichloro(2-methylpyridine)platinium;Picoplatin;(Sp-4-3)-amminedichloro(2-methylpyridine)platinium;Amd 473;Amd-473;Jm-473;Platinum, amminedichloro(2-methylpyridine)-, (sp-4-3)-
• CAS NO: 181630-15-9
• Molecular Formula: C₆H₁₀Cl₂N₂Pt
• Molecular Weight: 359.114
• Product Categories: Anti-cancer&immunity
• Mol File: 181630-15-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 127.5°Cat760mmHg
• Flash Point: 26.1°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 13.5mmHg at 25°C
• CAS DataBase Reference: Picoplatin(CAS DataBase Reference)
• NIST Chemistry Reference: Picoplatin(181630-15-9)
• EPA Substance Registry System: Picoplatin(181630-15-9)

Safety Data

• RIDADR: 2811
• HazardClass: 6.1(a)
• PackingGroup: II
• Hazardous Substances Data: 181630-15-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 181630-15-9 differently. You can refer to the following data:
1. Treatment of cancer.
2. Picoplatin is an extended spectrum of antineoplastic activity.

InChI:InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2

Upstream product

• 109-06-8 α-picoline 
• 15663-27-1 cisplatin 
• 181630-47-7 cis-amminediiodo(2-picoline)platinum(II) 
• 7647-01-0 hydrogenchloride 
• 1200317-36-7 ammineiodochloro(2-picoline)platinum(II) 
• 66705-99-5 potassium trichloro(2-picoline)platinate 
• 1336-21-6 ammonium hydroxide 
• 10025-99-7 potassium tetrachloroplatinate(II) 
• 631-61-8 ammonium acetate 
• 20574-25-8 K{PtaCl₃}*H₂O 
• 52613-97-5 cis-{Pt(2-methylpyridine)2Cl₂} 

Relevant articles and documents

Chromatin Regulates Genome Targeting with Cisplatin

Cisplatin derivatives can form various types of DNA lesions (DNA-Pt) and trigger pleiotropic DNA damage responses. Here, we report a strategy to visualize DNA-Pt with high resolution, taking advantage of a novel azide-containing derivative of cisplatin we named APPA, a cellular pre-extraction protocol and the labeling of DNA-Pt by means of click chemistry in cells. Our investigation revealed that pretreating cells with the histone deacetylase (HDAC) inhibitor SAHA led to detectable clusters of DNA-Pt that colocalized with the ubiquitin ligase RAD18 and the replication protein PCNA. Consistent with activation of translesion synthesis (TLS) under these conditions, SAHA and cisplatin cotreatment promoted focal accumulation of the low-fidelity polymerase Polη that also colocalized with PCNA. Remarkably, these cotreatments synergistically triggered mono-ubiquitination of PCNA and apoptosis in a RAD18-dependent manner. Our data provide evidence for a role of chromatin in regulating genome targeting with cisplatin derivatives and associated cellular responses.

VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS

The present invention relates to a new compound for visualizing DNA-platinum crosslink, and its use as a research tool and in screening method for identifying candidate drug to be used in combination with platinating compounds such as cisplatin, carboplatin, and oxaliplatin. Formulae (I), (II) or (III). The project leading to this application has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No [647973]).

Photoactive trans ammine/amine diazido platinum(IV) complexes

The synthesis and characterisation of eight new octahedral PtIV complexes of the type trans,trans,trans-[Pt(N3)2(OH)2(NH3)(Am)] where Am = methylamine (2), ethylamine (4), thiazole (6), 2-picoline (8)